Recently, phase 3 trials showed that NSCLC patients treated with ICI plus platinum‐based chemotherapy as first‐line treatment had a higher objective response rate (ORR), longer median progression‐free survival (PFS), and longer median OS than those treated with chemotherapy alone, regardless of the PD‐L1 TPS.7, 8, 9, 10, 11. Here, CD274 is linked to non-small cell lung carcinoma.